Patents Assigned to Tularik
  • Patent number: 7928137
    Abstract: Compounds of formula I in which R1, R2, R3, each X, L, Y, Cy, Lp, D and n have the meanings as set out in the specification, and corresponding compounds in which the unsubstituted or substituted amidine group is replaced with an unsubstituted or substituted aminomethyl group, are useful as serine protease inhibitors.
    Type: Grant
    Filed: March 2, 2007
    Date of Patent: April 19, 2011
    Assignee: Tularik Limited
    Inventors: John Walter Liebeschuetz, William Alexander Wylie, Bohdan Waszkowycz, Christopher William Murray, Andrew David Rimmer, Pauline Mary Welsh, Stuart Donald Jones, Jonathan Michael Ernest Roscoe, Stephen Clinton Young, Phillip John Morgan
  • Patent number: 7381734
    Abstract: Compounds of formula (I) where R5, R6a, each X, L, Cy and Lp are as defined in the specification, are tryptase inhibitors useful as antiinflammatory agents.
    Type: Grant
    Filed: July 22, 2005
    Date of Patent: June 3, 2008
    Assignee: Tularik Limited
    Inventors: Sarah Elizabeth Lively, Bohdan Waszkowycz, Martin James Harrison, Christopher Neil Farthing, Keith Michael Johnson
  • Publication number: 20070155777
    Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.
    Type: Application
    Filed: February 21, 2007
    Publication date: July 5, 2007
    Applicants: Tularik Inc.
    Inventors: Simon Burkitt, Mario Cardozo, Timothy Cushing, Michael DeGraffeneid, Christopher Farthing, Xiaolin Hao, Juan Jaen, Xian Jiao, David Kopecky, Marc Labelle, Sarah Lively, Dustin McMinn, Sven Rasmussen, Youngsook Shin, Andrew Smith, Marie-Louise Smith
  • Patent number: 7220781
    Abstract: Compounds of formula I in which R1, R2, R3, each X, L, Y, Cy, Lp, D and n have the meanings as set out in the specification, and corresponding compounds in which the unsubstituted or substituted amidine group is replaced with an unsubstituted or substituted aminomethyl group, are useful as serine protease inhibitors.
    Type: Grant
    Filed: January 8, 2004
    Date of Patent: May 22, 2007
    Assignee: Tularik Limited
    Inventors: John Walter Liebeschuetz, William Alexander Wylie, Bohdan Waszkowycz, Christopher William Murray, Andrew David Rimmer, Pauline Mary Welsh, Stuart Donald Jones, Jonathan Michael Ernest Roscoe, Stephen Clinton Young, Phillip John Morgan
  • Patent number: 7157585
    Abstract: Compounds of formula (I) where R5, R6a, each X, L, Cy and Lp are as defined in the specification, are tryptase inhibitors useful as antiinflammatory agents.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: January 2, 2007
    Assignee: Tularik Limited
    Inventors: Sarah Elizabeth Lively, Bohdan Waszkowycz, Martin James Harrison, Christopher Neil Farthing, Keith Michael Johnson
  • Publication number: 20060264424
    Abstract: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment or prevention of lipid disorders, metabolic disorders and cell-proliferative diseases. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in cholesterol metabolism. The subject compounds are particularly useful in the treatment of obesity, diabetes, hypercholesterolemia, atherosclerosis and hypolipoproteinemia.
    Type: Application
    Filed: August 11, 2004
    Publication date: November 23, 2006
    Applicant: Tularik Inc
    Inventors: Martin Harrison, Xian Jiao, Stuart Jones, Frank Kayser, David Kopecky
  • Publication number: 20060166309
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of four novel G-protein coupled receptors that are amplified in breast cancer cells, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of G-protein coupled receptors.
    Type: Application
    Filed: December 20, 2001
    Publication date: July 27, 2006
    Applicant: Tularik Inc.
    Inventors: Scott Powers, Jianxin Yang, Gene Cutler
  • Patent number: 7074934
    Abstract: Compounds of formula (I) where R2, each X, L, Y, Cy, Lp, D and n are as defined in the specification, are serine protease inhibitors useful as antithrombotic agents.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: July 11, 2006
    Assignee: Tularik Limited
    Inventors: Sarah Elizabeth Lively, Bohdan Waszkowycz, Martin James Harrison, Christopher Neil Farthing, Keith Michael Johnson
  • Patent number: 7067516
    Abstract: Compounds of formula (I) where R5, R6a, each X, L, Cy and Lp are as defined in the specification, are tryptase inhibitors useful as antiinflammatory agents.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: June 27, 2006
    Assignee: Tularik Limited
    Inventors: Sarah Elizabeth Lively, Martin James Harrison, Neil Jason Naylor, Christopher Neil Farthing, Bohdan Waszkowycz
  • Publication number: 20050255549
    Abstract: The present invention provides nucleic acids and polypeptides for IRAK-4, a novel member of the IRAK family of protein kinases. Members of the IRAK family are indispensable signal transducer for members of the IL-1R/Toll family of transmembrane receptors, including IL-1 receptors, IL-18 receptors and LPS receptors. IRAK-4 sequences from human and mouse are provided, as are methods for identifying compounds useful in the treatment or prevention of inflammatory diseases.
    Type: Application
    Filed: November 15, 2004
    Publication date: November 17, 2005
    Applicant: Tularik Inc.
    Inventors: Holger Wesche, Shyun Li
  • Patent number: 6962929
    Abstract: The invention provides methods and compositions relating to novel pentafluorophenylsulfonamide derivatives and analogs and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, vascular restenosis, microbial infections, and psoriasis, or as lead compounds for the development of such agents.
    Type: Grant
    Filed: October 11, 2002
    Date of Patent: November 8, 2005
    Assignee: Tularik Inc.
    Inventors: John A. Flygare, Julio Cesar Medina, Bei Shan, David Louis Clark, Terry J. Rosen
  • Publication number: 20050214850
    Abstract: The present invention provides polypeptides of a novel ABC family cholesterol transporter, SSG. The herein-disclosed sequences can be used for any of a number of purposes, including for the diagnosis and treatment of cholesterol-associated disorders, including sitosterolemia, and for the identification of molecules that associate with and/or modulate the activity of SSG.
    Type: Application
    Filed: May 11, 2005
    Publication date: September 29, 2005
    Applicant: Tularik Inc.
    Inventors: Hui Tian, Joshua Schultz, Bei Shan
  • Publication number: 20050182245
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of novel receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of the receptors.
    Type: Application
    Filed: March 21, 2005
    Publication date: August 18, 2005
    Applicant: Tularik Inc.
    Inventors: Hui Tian, Jiagang Zhao, Jin-Long Chen, Gene Cutler
  • Publication number: 20050170397
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of novel G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of G-protein coupled receptors.
    Type: Application
    Filed: January 18, 2005
    Publication date: August 4, 2005
    Applicant: Tularik Inc.
    Inventors: Hui Tian, Jiagang Zhao, Jin-Long Chen, Gene Cutler, Songzhu An, Kang Dai, Jamila Gupte
  • Patent number: 6916957
    Abstract: Compounds of formula (I) where R5, R6a, each X, L, Cy and Lp are as defined in the specification, are tryptase inhibitors useful as antiinflammatory agents.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: July 12, 2005
    Assignee: Tularik Limited
    Inventors: Sarah Elizabeth Lively, Bohdan Waszkowycz, Martin James Harrison, Christopher Neil Farthing, Keith Michael Johnson
  • Publication number: 20050070545
    Abstract: Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the activity of proteins involved in lipid metabolism and cell proliferation.
    Type: Application
    Filed: August 6, 2004
    Publication date: March 31, 2005
    Applicants: Tularik Inc., Japan Tobacco, Inc.
    Inventors: Brian Fox, Kiyosei Iio, Takashi Inaba, Frank Kayser, Kexue Li, Shoichi Sagawa, Masahiro Tanaka, Atsuhito Yoshida
  • Patent number: 6869975
    Abstract: Compounds, compositions and methods that are useful for the treatment of metabolic disorders, inflammatory diseases and cancer are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in lipid metabolism, inflammation and cell proliferation. The subject compounds are linked biaryl compounds.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: March 22, 2005
    Assignees: Tularik Inc., Japan Tobacco, Inc.
    Inventors: Hiroyuki Abe, Jonathan Houze, Hisashi Kawasaki, Frank Kayser, Rajiv Sharma, Samuel Sperry
  • Publication number: 20050026194
    Abstract: There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing a gene, which is amplified in many types of cancer. The amplified genes, their expressed protein products and antibodies are used diagnostically or as targets for cancer therapy or as vaccines; they also are used to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.
    Type: Application
    Filed: June 15, 2004
    Publication date: February 3, 2005
    Applicant: Tularik Inc.
    Inventor: David Mu
  • Publication number: 20050004059
    Abstract: There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing a gene, which is amplified in many types of cancer. The amplified gene, its expressed protein products and antibodies are used diagnostically or as targets for cancer therapy or as vaccines; they also are used to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.
    Type: Application
    Filed: April 5, 2004
    Publication date: January 6, 2005
    Applicant: Tularik Inc.
    Inventor: Jianxin Yang
  • Publication number: 20040259918
    Abstract: The present invention provides pharmaceutical compositions and methods for the treatment of diabetes mellitus using combination therapy. The compositions relate to a compound of Formula I and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, &agr;-glucosidase inhibitors, potassium channel antagonists, aldose reductase inhibitors, glucagon antagonists, activators of RXR, insulin therapy or other anti-obesity agent. The methods include the administration of the combination of compound of Formula I with antidiabetic agent where the two components are delivered in a simultaneous manner, where the compound of Formula I is administered first, followed by the antidiabetic agent, as well as wherein the antidiabetic agent is delivered first followed by the compound of Formula I.
    Type: Application
    Filed: June 5, 2003
    Publication date: December 23, 2004
    Applicant: Tularik Inc.
    Inventors: Juan C. Jaen, Jin-Long Chen